AR064429A1 - Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales. - Google Patents
Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales.Info
- Publication number
- AR064429A1 AR064429A1 ARP070105706A ARP070105706A AR064429A1 AR 064429 A1 AR064429 A1 AR 064429A1 AR P070105706 A ARP070105706 A AR P070105706A AR P070105706 A ARP070105706 A AR P070105706A AR 064429 A1 AR064429 A1 AR 064429A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- heterocycloalkyl
- aryl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Composiciones farmacéuticas para tratar o prevenir una infeccion viral o un trastorno relacionado con virus en un paciente. Reivindicacion 1: Un compuesto que tiene la formula (1), o una sal aceptable para uso farmacéutico, solvatos, profármaco o éster del mismo donde el anillo Z de la formula (1) es un ciclohexilo, ciclohexenilo, heterocicloalquilo de 6 miembros, heterocicloalquenilo de 6 miembros, arilo de 6 miembros o heteroarilo de 6 miembros, donde el anillo Z puede estar: (i) sustituido en forma opcional sobre uno o más átomos de carbono anulares con sustituyentes, que son iguales o diferentes, y que se seleccionan de alquilo, alquenilo, arilo, heteroarilo, cicloalquilo, heterocicloalquilo, halo, haloalquilo, hidroxialquilo, hidroxi, -CN, -C(O)R8, -C(O)OR9, -C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]qN(R9)2, -NHC(O)R8, -NHSO2R11, -S(O)pR11 o -SO2N(R9)2; y/o (ii) sustituido en forma opcional sobre un átomo de nitrogeno anular con sustituyentes, que son iguales o diferentes, y que se seleccionan de alquilo, arilo, haloalquilo, heteroarilo, hidroxialquilo, -C(O)R8, -C(O)OR9, -C(O)N(R9)2, -[C(R12)2]r-OR9, -[C(R12)2]rN(R9)2, -NHC(O)R8, -NHSO2R11, -S(O)pR11 o -SO2N(R9)2; R1 es un enlace, -[C(R12)2]r-, - [C(R12)2]r-O-[C(R12)2]q-, -[C(R12)2]r-N(R9)-[C(R12)2]q-, -[C(R12)2]q-CH=CH-[C(R12)2]q-, -[C(R12)2]q-C:::C-[C(R12)2]q- o -[C(R12)2]q-SO2-[C(R12)2]q-; R2 es -C(O)R9, -C(O)OR9, -C(O)OCH2OR9, -C(O)N(R9)2, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, - [C(R12)2]q-C(O)N(R9)C=N(R9)2, -[C(R12)2]q-arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-C(O)N(R9)SOR11, -[C(R12)2]q- C(O)N(R9)SO2R11, -[C(R12)2]q-C(O)N(R9)SO2N(R9)2, alquilo, grupo de formulas (2), donde un grupo arilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo o heteroarilo puede estar sustituido en forma opcional con hasta 4 sustituyentes, que se seleccionan cada uno en forma independiente de alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q- heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2)q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, - [C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; R3 es H, -[C(R12)2]q-alquilo, -[C(R12)2]q-arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heteroarilo o - [C(R12)2]q-heterocicloalquenilo, grupo de formulas (3) donde un grupo arilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo o heteroarilo puede estar sustituido en forma opcional con hasta 3 sustituyentes, que son iguales o diferentes, y se seleccionan de alquilo, arilo, heteroaril-, halo, haloalquilo, hidroxialquilo, hidroxi, -CN, -C(O)R8, -C(O)OR9, -C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -NHC(O)R8, -NHSO2R11, -S(O)pR11 o -SO2N(R9)2; R6 y R7 son cada uno, en forma independiente, H, alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q- hidroxialquilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2)q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q- SO2N(R9)2 o -SO2N(R9)C(O)N(R9)2; cada aparicion de R8 es independientemente H, alquilo, alquenilo, alquinilo, -[C(R12)2]q-arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, - [C(R12)2]q-heteroarilo, haloalquilo o hidroxialquilo; cada aparicion de R9 es independientemente H, alquilo, alquenilo, alquinilo, -[C(R12)2]q-arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q- heterocicloalquenilo, -[C(R12)2]q-heteroarilo, haloalquilo o hidroxialquilo; R10 es H, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo, heteroarilo, donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo o heteroarilo puede estar sustituido en forma opcional e independiente con hasta 4 sustituyentes, que se seleccionan en forma independiente de H, alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q- cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q- C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2, de modo tal que cuando R1 es un enlace, R10 no es H; cada aparicion de R11 es independientemente alquilo, arilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, heteroarilo, haloalquilo, hidroxi o hidroxialquilo, donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo o heteroarilo puede estar sustituido en forma opcional e independiente con hasta 4 sustituyentes, que se seleccionan en forma independiente de -H, alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, - [C(R12)2]q-cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q- C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2alquilo, -[C(R12)2]q-NHSO2cicloalquilo, -[C(R12)2]q-NHSO2arilo, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; cada aparicion de R12 es independientemente H, halo, -N(R9)2, -OR9, alquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo, donde un grupo cicloalquilo, cicloalquenilo, heterocicloalquilo o heterocicloalquenilo puede estar sustituido en forma opcional e independiente con hasta 4 sustituyentes, que se seleccionan en forma independiente de alquilo, halo, haloalquilo, hidroxialquilo, hidroxi, -CN, -C(O)alquilo, -C(O)Oalquilo, -C(O)NHalquilo, -C(O)N(alquilo)2, -O-alquilo, -NH2, -NH(alquilo), -N(alquilo)2, -NHC(O)alquilo, -NHSO2aIquilo, -SO2alquiIo o -SO2NH-alquilo, o dos grupos R12, se unen con los átomos de carbono a los que están unidos, para formar un grupo cicloalquilo, heterocicloalquilo o C=O; cada aparicion de R20 es independientemente H, alquilo, arilo, cicloalquilo, heterocicloalquilo o heteroarilo, o ambos grupos R20 y los átomos de carbono a los que están unidos, se unen para formar un grupo cicloalquilo, cicloheteroalquilo, arilo o heteroarilo donde un cicloalquilo, cicloheteroalquilo, arilo o heteroarilo puede estar sustituido con hasta 4 grupos, que se seleccionan en forma independiente de alquilo, alquenilo, alquinilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q- cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q-C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q- NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 y -SO2N(R9)C(O)N(R9)2; cada aparicion de R30 es independientemente H, alquilo, alquenilo, alquinilo, arilo, -[C(R12)2]q-cicloalquilo, -[C(R12)2]q- cicloalquenilo, -[C(R12)2]q-heterocicloalquilo, -[C(R12)2]q-heterocicloalquenilo, -[C(R12)2]q-heteroarilo, -[C(R12)2]q-haloalquilo, -[C(R12)2]q-hidroxialquilo, halo, hidroxi, -OR9, -CN, -[C(R12)2]q-C(O)R8, -[C(R12)2]q-C(O)OR9, -[C(R12)2]q- C(O)N(R9)2, -[C(R12)2]q-OR9, -[C(R12)2]q-N(R9)2, -[C(R12)2]q-NHC(O)R8, -[C(R12)2]q-NR8C(O)N(R9)2, -[C(R12)2]q-NHSO2R11, -[C(R12)2]q-S(O)pR11, -[C(R12)2]q-SO2N(R9)2 o -SO2N(R9)C(O)N(R9)2, o dos grupos R30 adyacentes, junto con los átomos de carbono a los que están unidos, se unen para formar un anillo de 3 a 7 miembros seleccionado de arilo, cicloalquilo, heteroarilo y heterocicloalquilo; cada aparicion de p es independientemente 0, 1 o 2; cada aparicion de q es independientemente un numero entero que oscila entre 0 y 4; y cada aparicion de r es independientemente un numero entero que oscila entre 1 y 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87661306P | 2006-12-22 | 2006-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR064429A1 true AR064429A1 (es) | 2009-04-01 |
Family
ID=39185892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070105706A AR064429A1 (es) | 2006-12-22 | 2007-12-18 | Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales. |
Country Status (14)
Country | Link |
---|---|
US (1) | US8546420B2 (es) |
EP (1) | EP2064181A1 (es) |
JP (3) | JP5211068B2 (es) |
KR (1) | KR20090106539A (es) |
CN (1) | CN101611002A (es) |
AR (1) | AR064429A1 (es) |
AU (1) | AU2007339386B8 (es) |
CA (1) | CA2673254C (es) |
CL (1) | CL2007003685A1 (es) |
MX (1) | MX2009006878A (es) |
PE (1) | PE20081567A1 (es) |
TW (1) | TW200833662A (es) |
WO (1) | WO2008082488A1 (es) |
ZA (1) | ZA200904334B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110104109A1 (en) * | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
KR20090106539A (ko) | 2006-12-22 | 2009-10-09 | 쉐링 코포레이션 | Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
MX2009006880A (es) | 2006-12-22 | 2009-07-03 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas. |
CA2674831A1 (en) | 2006-12-22 | 2008-11-13 | Schering Corporation | 5,6-ring annulated indole derivatives and methods of use thereof |
CN101842374A (zh) * | 2007-08-29 | 2010-09-22 | 先灵公司 | 用于治疗病毒感染的2,3-取代的氮杂吲哚衍生物 |
ES2447543T3 (es) * | 2007-08-29 | 2014-03-12 | Merck Sharp & Dohme Corp. | Derivados de indol sustituidos y métodos de utilización de los mismos |
CA2705587A1 (en) * | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
MX2010005356A (es) * | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
WO2009152200A1 (en) * | 2008-06-13 | 2009-12-17 | Schering Corporation | Tricyclic indole derivatives and methods of use thereof |
CA2730517A1 (en) * | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
SG172778A1 (en) | 2008-12-22 | 2011-08-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
JP2013512246A (ja) | 2009-11-25 | 2013-04-11 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体 |
JP2013515068A (ja) | 2009-12-22 | 2013-05-02 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法 |
CA2792121A1 (en) | 2010-03-09 | 2011-09-15 | Merck Sharp & Dohme Corp. | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
KR101213495B1 (ko) | 2010-06-03 | 2013-01-14 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
AU2011286276A1 (en) | 2010-07-26 | 2013-01-24 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
JP2013540122A (ja) | 2010-09-29 | 2013-10-31 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法 |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
JP2014515023A (ja) | 2011-04-13 | 2014-06-26 | メルク・シャープ・アンド・ドーム・コーポレーション | 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法 |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
US20140378416A1 (en) | 2011-09-14 | 2014-12-25 | Michael P. Dwyer | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2014059902A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
MX2015006248A (es) | 2012-11-19 | 2015-08-14 | Merck Sharp & Dohme | Derivados de nucleosido 2'-alquinilo sustituido para el tratamiento de enfermedades virales. |
WO2014204831A1 (en) | 2013-06-18 | 2014-12-24 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2014205593A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
WO2014205592A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Heterocyclic compounds and methods of use thereof for treatment of hepatitis c |
WO2015065817A1 (en) | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
WO2017223012A1 (en) | 2016-06-20 | 2017-12-28 | Merck Sharp & Dohme Corp. | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
CN106619731B (zh) * | 2016-12-30 | 2020-06-12 | 昆明赛诺制药股份有限公司 | 一种治疗丙型肝炎的药物 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE648639C (de) | 1935-05-19 | 1937-08-05 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von Dipyrrolen |
US3632805A (en) | 1967-12-08 | 1972-01-04 | Sumitomo Chemical Co | Process for producing 1-aminoalkyl-benzodiazepine derivatives |
AU575854B2 (en) | 1983-10-04 | 1988-08-11 | Shionogi & Co., Ltd. | 7beta-(carboxyalkenamido) cephalosporins |
NZ220764A (en) | 1986-07-02 | 1989-09-27 | Shionogi & Co | Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions |
US5017380A (en) | 1986-07-02 | 1991-05-21 | Shionogi & Co., Ltd. | Gelatin hard capsule containing crystalline hydrate of oral cephalosporin |
CA2038925A1 (en) | 1990-03-26 | 1991-09-27 | Takashi Sohda | Indole derivatives, their production and use |
JPH04149429A (ja) | 1990-10-12 | 1992-05-22 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法 |
ZA939516B (en) * | 1992-12-22 | 1994-06-06 | Smithkline Beecham Corp | Endothelin receptor antagonists |
JPH0753558A (ja) * | 1993-08-10 | 1995-02-28 | Shionogi & Co Ltd | デュオカルマイシンsa及びその誘導体の製造法 |
EP0766684A4 (en) * | 1994-06-09 | 1997-07-16 | Smithkline Beecham Corp | ENDOTHELINE RECEPTOR ANTAGONISTS |
WO1995033748A1 (en) * | 1994-06-09 | 1995-12-14 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
WO1996018393A1 (en) * | 1994-12-13 | 1996-06-20 | Smithkline Beecham Corporation | Novel compounds |
IT1278077B1 (it) | 1995-05-25 | 1997-11-17 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal |
GB9526495D0 (en) * | 1995-12-23 | 1996-02-28 | Knoll Ag | Therapeutic agents |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
CA2294562C (en) | 1997-08-11 | 2005-07-26 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
FR2768146B1 (fr) | 1997-09-05 | 2000-05-05 | Oreal | Nouveaux composes de la famille des indole-carboxyliques et leur utilisation |
AU2001253124A1 (en) | 2000-04-05 | 2001-10-23 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
HUP0302957A2 (hu) | 2000-04-19 | 2003-12-29 | Schering Corporation | Hepatitis C vírus alkil- és aril-alanin P2 csoportokat tartalmazó makrociklusos NS-3 szerin proteáz inhibitorai |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
DK1385870T3 (da) | 2000-07-21 | 2010-07-05 | Schering Corp | Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus |
US7169760B2 (en) | 2000-07-21 | 2007-01-30 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
JP2004529855A (ja) | 2000-10-10 | 2004-09-30 | スミスクライン ビーチャム コーポレーション | 置換インドール類、そのような置換インドール類を含む医薬組成物及びPPAR−γ結合剤としてのそれらの使用 |
CA2430458A1 (en) | 2000-12-12 | 2002-06-20 | Schering Corporation | Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
CA2430808A1 (en) | 2000-12-18 | 2002-06-27 | Eli Lilly And Company | Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases |
JP2004529887A (ja) * | 2001-02-22 | 2004-09-30 | スクール オブ ファーマシー, ユニヴァーシティ オブ ロンドン | 腫瘍治療のためのプロドラッグとしてのピロロ−インドールおよびピロロ−キノリン誘導体 |
EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
JP2003342276A (ja) * | 2002-05-24 | 2003-12-03 | Mitsui Chemicals Inc | ピロロキナゾリン誘導体及び農園芸用有害生物防除剤ならびにその使用方法 |
JP2006505571A (ja) | 2002-10-15 | 2006-02-16 | リゲル ファーマシューテイカルズ、インコーポレイテッド | 置換されたインドール及びhcv阻害剤としてのその使用 |
US20050075331A1 (en) | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
ATE546456T1 (de) | 2003-05-30 | 2012-03-15 | Gemin X Pharmaceuticals Canada Inc | Triheterocyclische verbindungen, zusammensetzungen, und verfahren zur behandlung von krebs |
GB0323845D0 (en) | 2003-10-10 | 2003-11-12 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
WO2005047324A2 (en) | 2003-11-10 | 2005-05-26 | Schering Corp | ANTI-INTERLEUKIN ANTIBODY-10 |
JP4714732B2 (ja) | 2004-02-27 | 2011-06-29 | シェーリング コーポレイション | C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしての硫黄化合物 |
BRPI0508079A (pt) | 2004-03-01 | 2007-07-17 | Viropharma Inc | composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c |
US20050249702A1 (en) | 2004-05-06 | 2005-11-10 | Schering Corporation | (1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease |
EP1604988A1 (en) | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7250441B2 (en) | 2004-09-23 | 2007-07-31 | Wyeth | Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus |
DE102004047272A1 (de) | 2004-09-24 | 2006-04-06 | Schering Ag | Inhibitoren der löslichen Adenylatzyklase |
AU2005298412B2 (en) | 2004-10-26 | 2011-06-09 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
JP4149429B2 (ja) | 2004-10-26 | 2008-09-10 | 本田技研工業株式会社 | 車両の走行安全装置 |
MX2007008587A (es) | 2005-01-14 | 2007-09-07 | Genelabs Tech Inc | Derivados de indol para tratamiento de infecciones virales. |
US20110104109A1 (en) | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7482360B2 (en) | 2005-09-23 | 2009-01-27 | Schering Corporation | Fused tetracyclic mGluR1 antagonists as therapeutic agents |
JP2009523732A (ja) | 2006-01-13 | 2009-06-25 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎の治療方法 |
EP1981524A2 (en) | 2006-02-09 | 2008-10-22 | Schering Corporation | Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto |
MX2009006880A (es) | 2006-12-22 | 2009-07-03 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas. |
KR20090106539A (ko) | 2006-12-22 | 2009-10-09 | 쉐링 코포레이션 | Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
CA2674831A1 (en) | 2006-12-22 | 2008-11-13 | Schering Corporation | 5,6-ring annulated indole derivatives and methods of use thereof |
CN101842374A (zh) | 2007-08-29 | 2010-09-22 | 先灵公司 | 用于治疗病毒感染的2,3-取代的氮杂吲哚衍生物 |
ES2447543T3 (es) | 2007-08-29 | 2014-03-12 | Merck Sharp & Dohme Corp. | Derivados de indol sustituidos y métodos de utilización de los mismos |
PE20090995A1 (es) | 2007-08-29 | 2009-08-03 | Schering Corp | Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc) |
CA2705587A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
MX2010005356A (es) | 2007-11-16 | 2010-05-27 | Schering Corp | Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos. |
-
2007
- 2007-12-17 KR KR1020097015272A patent/KR20090106539A/ko not_active Application Discontinuation
- 2007-12-17 EP EP07863006A patent/EP2064181A1/en not_active Withdrawn
- 2007-12-17 CN CNA2007800517016A patent/CN101611002A/zh active Pending
- 2007-12-17 MX MX2009006878A patent/MX2009006878A/es unknown
- 2007-12-17 AU AU2007339386A patent/AU2007339386B8/en not_active Ceased
- 2007-12-17 JP JP2009542841A patent/JP5211068B2/ja not_active Expired - Fee Related
- 2007-12-17 CA CA2673254A patent/CA2673254C/en not_active Expired - Fee Related
- 2007-12-17 US US12/519,728 patent/US8546420B2/en not_active Expired - Fee Related
- 2007-12-17 WO PCT/US2007/025765 patent/WO2008082488A1/en active Application Filing
- 2007-12-18 AR ARP070105706A patent/AR064429A1/es not_active Application Discontinuation
- 2007-12-18 CL CL200703685A patent/CL2007003685A1/es unknown
- 2007-12-18 TW TW096148494A patent/TW200833662A/zh unknown
-
2008
- 2008-01-02 PE PE2008000056A patent/PE20081567A1/es not_active Application Discontinuation
-
2009
- 2009-06-19 ZA ZA200904334A patent/ZA200904334B/xx unknown
-
2013
- 2013-01-23 JP JP2013009838A patent/JP2013121970A/ja active Pending
- 2013-01-23 JP JP2013009837A patent/JP2013100331A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2013100331A (ja) | 2013-05-23 |
JP2010513494A (ja) | 2010-04-30 |
CL2007003685A1 (es) | 2008-06-27 |
PE20081567A1 (es) | 2008-12-06 |
WO2008082488A1 (en) | 2008-07-10 |
EP2064181A1 (en) | 2009-06-03 |
CA2673254A1 (en) | 2008-07-10 |
AU2007339386B2 (en) | 2013-08-08 |
MX2009006878A (es) | 2009-07-07 |
US20100196319A1 (en) | 2010-08-05 |
JP2013121970A (ja) | 2013-06-20 |
AU2007339386A8 (en) | 2013-12-05 |
AU2007339386A1 (en) | 2008-07-10 |
US8546420B2 (en) | 2013-10-01 |
CA2673254C (en) | 2013-09-10 |
KR20090106539A (ko) | 2009-10-09 |
JP5211068B2 (ja) | 2013-06-12 |
ZA200904334B (en) | 2010-06-30 |
CN101611002A (zh) | 2009-12-23 |
AU2007339386B8 (en) | 2013-12-05 |
TW200833662A (en) | 2008-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR064429A1 (es) | Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales. | |
AR064428A1 (es) | Derivados indolicos con anillo unido en las posiciones 4,5 y sus metodos de uso. composiciones farmaceuticas | |
AR068106A1 (es) | Derivados de indol 2-carboxi sustituidos y una composicion farmaceutica | |
AR068108A1 (es) | Derivados azaindol 2,3-sustituidos y una composicion farmaceutica | |
AR064430A1 (es) | Derivados indolicos con anillo unido en las posiciones 5,6 . composiciones farmaceuticas y uso de los mismos. | |
AR068107A1 (es) | Derivados indolicos 2,3 sustituidos y una composicion farmaceutica | |
AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
MX2019000123A (es) | Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores. | |
AR063545A1 (es) | Derivados de tiazoles -1,3 aminosustituidos, composiciones farmaceuticas que las contienen y usos como agentes anticancer | |
AR051469A1 (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
AR049170A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
RU2010123989A (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
HRP20181036T1 (hr) | 2,6-supstituirani derivati purina i njihova upotreba u liječenju proliferativnih poremećaja | |
AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
AR101106A1 (es) | Inhibidores de tirosina quinasa de bruton | |
SI2997033T1 (en) | FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS | |
AR084976A1 (es) | Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
AR015312A1 (es) | Compuestos inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunesy respiratorias, composicion farmaceutica y uso de los compuestos en la preparacion de medicamentos | |
TN2019000170A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
AR059523A2 (es) | Azalidas de 13 miembros macrolidos, composiciones farmaceuticas, su uso en la preparacion de medicamentos para el tratamiento de infecciones y procedimientos para preparar estos compuestos. | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
AR043367A2 (es) | Derivados de benzofenona, composiciones farmaceuticas y procesos de preparacion. | |
AR019789A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |